Review and evaluation of vancomycin dosing guidelines for obese individuals

References

• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Clin Infect Dis. 2020;71(6):1361–1364.
   PubMed Web of Science ®Google Scholar
• Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975–981.
   PubMed Web of Science ®Google Scholar
• Jung Y, Song K-H, Cho J, et al. Area under the concentration–time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014;43(2):179–183.
   PubMed Web of Science ®Google Scholar
• Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–1663.
   PubMed Web of Science ®Google Scholar
• Zelenitsky S, Rubinstein E, Ariano R, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41(3):255–260.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 2012;58(4):308–312.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The emperor’s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536–1545.
   PubMed Web of Science ®Google Scholar
• Aljefri DM, Avedissian SN, Rhodes NJ, et al. Vancomycin area under the curve and acute kidney injury: a meta-analysis. Clin Infect Dis. 2019;69(11):1881–1887.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Murray KP, Trinh TD, et al. Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents Chemother. 2018;62(1):e01684–17.
   PubMedGoogle Scholar
• Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6(7):438–446.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Obesity: preventing and managing the global epidemic: report of a WHO consultation. Geneva: World Health Organisation; 2000 [cited 2021 Jun 20]. Available from: https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/.
   Google Scholar
• World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment: Health Communications Australia Pty Limited. 2000 [cited 2021 Jun 20]. Available from: https://apps.who.int/iris/bitstream/handle/10665/206936/0957708211_eng.pdf.
   Google Scholar
• Lim JU, Lee JH, Kim JS, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:2465.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.
   PubMed Web of Science ®Google Scholar
• Janson B, and Thursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012;25(6):634–649.
   PubMed Web of Science ®Google Scholar
• Jackson S, Leahy F, McGowan A, et al. Delayed gastric emptying in the obese: an assessment using the non‐invasive 13C‐octanoic acid breath test. Diabetes Obes Metab. 2004;6(4):264–270.
   PubMedGoogle Scholar
• Oyaert M, Spriet I, Allegaert K, et al. Factors impacting unbound vancomycin concentrations in different patient populations. Antimicrob Agents Chemother. 2015;59(11):7073–7079.
   PubMedGoogle Scholar
• Benedek I, Blouin R, McNamara P. Serum protein binding and the role of increased alpha 1‐acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol. 1984;18(6):941–946.
   PubMedGoogle Scholar
• Jain R, Chung S, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89.
   PubMed Web of Science ®Google Scholar
• Levy BI, Schiffrin EL, Mourad JJ, et al. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118(9):968–976.
   PubMedGoogle Scholar
• Meng L, Mui E, and Holubar MK, et al. Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy. 2017;37(11):1415–1431.
   PubMed Web of Science ®Google Scholar
• Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12(6):1211–1217.
   PubMed Web of Science ®Google Scholar
• Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278(5):F817–22.
   PubMed Web of Science ®Google Scholar
• Donato M, Jimenez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro. 2007;21(2):271–276.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RR. Structural features of vancomycin. Rev Infect Dis. 1981;3(Supplement):S205–S9.
   PubMedGoogle Scholar
• Hanrahan TP, Lipman J, Roberts JA. Antibiotic dosing in obesity: a BIG challenge. Crit Care. 2016;20(1):1–2.
   PubMedGoogle Scholar
• Patel S, Preuss CV, Bernice FV [Internet]. Treasure Island (FL): statPearls publishing. 2021 [cited 2021 Jul 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459263/.
   Google Scholar
• Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg. 1987;122(2):207–212.
   PubMed Web of Science ®Google Scholar
• Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575–580.
   PubMed Web of Science ®Google Scholar
• Vance-Bryan K, Guay D, Gilliland S, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993;37(3):436–440.
   PubMed Web of Science ®Google Scholar
• Bue M, Tøttrup M, Hanberg P, et al. Bone and subcutaneous adipose tissue pharmacokinetics of vancomycin in total knee replacement patients. Acta Orthop. 2018;89(1):95–100.
   PubMed Web of Science ®Google Scholar
• Krogstad DJ, RC MJR, Greenrlatt DJ. Single‐dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980;20(4):197–201.
   PubMedGoogle Scholar
• Butterfield JM, Patel N, Pai MP, et al. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277–4282.
   PubMed Web of Science ®Google Scholar
• Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory–based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. Pharmacotherapy. 2014;34(2):203–209.
   PubMedGoogle Scholar
• Benet LZ. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121.
   PubMed Web of Science ®Google Scholar
• Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant. 2008;23(12):3946–3952.
   PubMedGoogle Scholar
• Smit C, Wasmann RE, Goulooze SC, et al. Population pharmacokinetics of vancomycin in obesity: finding the optimal dose for (morbidly) obese individuals. Br J Clin Pharmacol. 2020;86(2):303–317.
   PubMed Web of Science ®Google Scholar
• Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, part I: in adults. Clin Pharmacokinet. 2020;59(6):671–698.
   PubMedGoogle Scholar
• Bauer L, Black D, Lill J. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621–625.
   PubMed Web of Science ®Google Scholar
• Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16(5):513–518.
   PubMedGoogle Scholar
• Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127–139.
   PubMedGoogle Scholar
• Crass RL, Dunn R, Hong J, et al. Dosing vancomycin in the super obese: less is more. J Antimicrob Chemother. 2018;73(11):3081–3086.
   PubMedGoogle Scholar
• Masich AM, Kalaria SN, Gonzales JP, et al. Vancomycin pharmacokinetics in obese patients with sepsis or septic shock. Pharmacotherapy. 2020;40(3):211–220.
   PubMed Web of Science ®Google Scholar
• Weller PF. Vancomycin hypersensitivity [Internet]. UpToDate. 2021 [cited 2021 Jul 1]. Available from: https://www.uptodate.com/contents/vancomycin-hypersensitivity.
   Google Scholar
• Hong J, Krop LC, Johns T, et al. Individualized vancomycin dosing in obese patients: a two‐sample measurement approach improves target attainment. Pharmacotherapy. 2015;35(5):455–463.
   PubMedGoogle Scholar
• Elyasi S, Khalili H. Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons. Eur J Clin Pharmacol. 2016;72(7):777–788.
   PubMed Web of Science ®Google Scholar
• Bakke V, Sporsem H, Von der Lippe E, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61(6):627–635.
   PubMed Web of Science ®Google Scholar
• Carter BL, Damer KM, Walroth TA, et al. A systematic review of vancomycin dosing and monitoring in burn patients. J Burn Care Res. 2015;36(6):641–650.
   PubMedGoogle Scholar
• Flannery AH, Bissell BD, Bastin MT, et al. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2020;48(6):912–918.
   PubMedGoogle Scholar
• Han P, Duffull S, Kirkpatrick C, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther. 2007;82(5):505–508.
   PubMed Web of Science ®Google Scholar
• Kanazawa M, Yoshiike N, Osaka T, et al. Criteria and classification of obesity in Japan and Asia‐Oceania. Asia Pac J Clin Nutr. 2002;11:S732–S7.
   Google Scholar
• Zhou BF. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut‐off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15(1):83–96.
   PubMed Web of Science ®Google Scholar
• Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J Antimicrob Chemother. 2016;71(11):3020–3025.
   PubMed Web of Science ®Google Scholar
• Mohd Zaher ZM, Zambari R, Chan SP, et al. Optimal cut-off levels to define obesity: body mass index and waist circumference, and their relationship to cardiovascular disease, dyslipidaemia, hypertension and diabetes in Malaysia. Asia Pac J Clin Nutr. 2009;18(2):209–216.
   PubMedGoogle Scholar
• Hirai T, Hanada K, Kanno A, et al. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment. Eur J Clin Pharmacol. 2019;75(6):859–866.
   PubMedGoogle Scholar
• Choi YC, Saw S, Soliman D, et al. Intravenous vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017;51(11):937–944.
   PubMedGoogle Scholar
• Davies SW, Efird JT, Guidry CA, et al. Vancomycin-associated nephrotoxicity: the obesity factor. Surg Infect (Larchmt). 2015;16(6):684–693.
   PubMedGoogle Scholar
• Mahmood I. Theoretical versus empirical allometry: facts behind theories application to pharmacokinetics. J Pharm Sci. 2010;99(7):2927–2933.
   PubMed Web of Science ®Google Scholar
• Brown ML, Hutchison AM, McAtee AM, et al. Allometric versus consensus guideline dosing in achieving target vancomycin trough concentrations. Am J Health Syst Pharm. 2017;74(14):1067–1075.
   PubMedGoogle Scholar
• Moreault O, Lacasse Y, Bussières JS. Calculating ideal body weight: keep it simple. Anesthesiology. 2017;127(1):203–204.
   PubMedGoogle Scholar
• Principles of vancomycin use. 2019. In: eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited [cited 2021 Aug 4]. Available from: https://tgldcdp.tg.org.au/viewTopic?topicfile=vancomycin-use-principles&guidelineName=Antibiotic&topicNavigation=navigateTopic.
   Google Scholar
• Shah B, Sucher K, Hollenbeck CB. Comparison of ideal body weight equations and published height‐weight tables with body mass index tables for healthy adults in the United States. Nutr Clin Pract. 2006;21(3):312–319.
   PubMedGoogle Scholar
• Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017;40(5):189.
   PubMedGoogle Scholar
• Leong JV, Boro MS, Winter ME. Determining vancomycin clearance in an overweight and obese population. Am J Health Syst Pharm. 2011;68(7):599–603.
   PubMed Web of Science ®Google Scholar
• Wesner AR, Brackbill ML, Coyle LL, et al. Prospective trial of a novel nomogram to achieve updated vancomycin trough concentrations. Interdiscip Perspect Infect Dis. 2013;2013:839456.
   PubMedGoogle Scholar
• Levey AS, Coresh J, Tighiouart H, et al. Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol. 2020;16(1):51–64.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
   PubMed Web of Science ®Google Scholar
• Stefani M, Singer RF, Roberts DM. How to adjust drug doses in chronic kidney disease. Aust Prescr. 2019;42(5):163.
   PubMedGoogle Scholar
• Nankivell BJ. Creatinine clearance and the assessment of renal function. Aust Prescr. 2001;24(1):15–17.
   Google Scholar
• Demirovic JA, Pai AB, and Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66(7):642–648.
   PubMed Web of Science ®Google Scholar
• Brown DL, Masselink AJ, Lalla CD. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation. Ann Pharmacother. 2013;47(7–8):1039–1044.
   PubMedGoogle Scholar
• Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft‐Gault equation. Pharmacotherapy. 2012;32(7):604–612.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Kale-Pradhan PB. Estimating creatinine clearance: a meta‐analysis. Pharmacotherapy. 2011;31(7):658–664.
   PubMedGoogle Scholar
• Bouquegneau A, Vidal‐Petiot E, Moranne O, et al. Creatinine‐based equations for the adjustment of drug dosage in an obese population. Br J Clin Pharmacol. 2016;81(2):349–361.
   PubMedGoogle Scholar
• Nyman HA, Dowling TC, Hudson JQ, et al. Comparative evaluation of the cockcroft‐gault equation and the modification of diet in renal disease (MDRD) study equation for drug dosing: an opinion of the nephrology practice and research network of the American college of clinical pharmacy. Pharmacotherapy. 2011;31(11):1130–1144.
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5–14.
   Web of Science ®Google Scholar
• Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Higdon EA, Kimmons LA, Duhart JBT, et al. Disagreement in estimates of kidney function for drug dosing in obese inpatients. J Pharm Pract. 2019;32(1):41–47.
   PubMedGoogle Scholar
• Park EJ, Pai MP, Dong T, et al. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother. 2012;46(3):317–328.
   PubMedGoogle Scholar
• Lodise T, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315–3320.
   PubMed Web of Science ®Google Scholar
• Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One. 2013;8(10):e77169.
   PubMed Web of Science ®Google Scholar
• Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62(2):e02042–17.
   PubMed Web of Science ®Google Scholar
• Colin PJ, Allegaert K, Thomson AH, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767–780.
   PubMed Web of Science ®Google Scholar
• Colin PJ, Eleveld DJ, and Hart A, et al. Do vancomycin pharmacokinetics differ between obese and non-obese patients? Comparison of a general-purpose and four obesity-specific pharmacokinetic models. Ther Drug Monit. 2021;43(1):126.
   PubMedGoogle Scholar
• Pharmacotherapeutic Compass. Vancomycin (intravenous) [Internet]. Netherlands: national health care institute. [cited 2021 Aug 4]. Available from: https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/v/vancomycine__intraveneus_.
   Google Scholar
• Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Infect Chemother. 2013;19(3):365–380.
   PubMed Web of Science ®Google Scholar
• He N, Su S, Ye Z, et al. Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society. Clin Infect Dis. 2020;71(Supplement_4):S363–S71.
   PubMedGoogle Scholar
• Ministry of Health Malaysia. National antimicrobial guideline. 3rd ed. Malaysia: Pharmaceutical Services Programme; 2019.
   Google Scholar
• Pharmacy Practice & Development Division. Clinical Pharmacokinetics Pharmacy Handbook. 2nd. Malaysia: Clinical Pharmacy Working Committee, Pharmacy Practice & Development Division, Ministry of Health Malaysia; 2019.
   Google Scholar
• Surrey and Sussex NHS. Vancomycin [Internet]. Surrey and sussex: surrey and sussex healthcare NHS trust. 2013 [cited 2021 Aug 8]. Available from: https://www.surreyandsussex.nhs.uk/wp-content/uploads/2013/04/Vancomycin-Therapeutic-Drug-Monitoring3.pdf.
   Google Scholar
• Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55(6):2704–2709.
   PubMed Web of Science ®Google Scholar
• Jeurissen A, Sluyts I, Rutsaert R. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents. 2011;37(1):75–77.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507–514.
   PubMed Web of Science ®Google Scholar
• Kaburaki S, Yoshimura E, Kojima N, et al. Improvement of renal function estimation equations for elderly Japanese people. Health Sci Rep. 2018;1(10):e85.
   PubMedGoogle Scholar
• Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11(1):41–50.
   PubMedGoogle Scholar
• Kubiak D W, Alquwaizani M, and Sansonetti D. An Evaluation of Systemic Vancomycin Dosing in Obese Patients. Open Forum Infectious Diseases. 2015;2(4). DOI:https://doi.org/10.1093/ofid/ofv176.
   Google Scholar
• Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147.
   PubMed Web of Science ®Google Scholar
• Reuter SE, Stocker SL, Alffenaar JWC, et al. Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2022;44(1):121–132.
   PubMedGoogle Scholar
• Baron KT, Gastonguay MR. Simulation from ODE-based population PK/PD and systems pharmacology models in R with mrgsolve. Omega (Westport). 2015;2:1x.
   Google Scholar
• Flannery AH, Hammond DA, and Oyler DR, et al. Vancomycin dosing practices among critical care pharmacists: a survey of society of critical care medicine pharmacists. Infect Dis (Auckl). 2020;13:1178633720952078.
   Google Scholar